Gadolinium Diethylenetriaminepentaacetic Acid Enhancement in Magnetic Resonance Imaging in Relation to Symptoms and Signs among Sciatic Patients

Spine ◽  
2002 ◽  
Vol 27 (13) ◽  
pp. 1433-1437 ◽  
Author(s):  
Reijo A. Autio ◽  
Jaro Karppinen ◽  
Mauno Kurunlahti ◽  
Eero Kyllönen ◽  
Heikki Vanharanta ◽  
...  
2012 ◽  
Vol 11 (4) ◽  
pp. 7290.2011.00047 ◽  
Author(s):  
Huedayi Korkusuz ◽  
Karsten Ulbrich ◽  
Verena Bihrer ◽  
Katerina Welzel ◽  
Valery Chernikov ◽  
...  

Different from regular small molecule contrast agents, nanoparticle-based contrast agents have a longer circulation time and can be modified with ligands to confer tissue-specific contrasting properties. We evaluated the tissue distribution of polymeric nanoparticles (NPs) prepared from human serum albumin (HSA), loaded with gadolinium–diethylenetriaminepentaacetic acid (Gd-DTPA) (Gd-HSA-NP), and coated with folic acid (FA) (Gd-HSA-NP-FA) in mice by magnetic resonance imaging (MRI). FA increases the affinity of the Gd-HSA-NP to FA receptor–expressing cells. Clinical 3 T MRI was used to evaluate the signal intensities in the different organs of mice injected with Gd-DTPA, Gd-HSA-NP, or Gd-HSA-NP-FA. Signal intensities were measured and standardized by calculating the signal to noise ratios. In general, the NP-based contrast agents provided stronger contrasting than Gd-DTPA. Gd-HSA-NP-FA provided a significant contrast enhancement (CE) in the brain ( p = .0032), whereas Gd-DTPA or Gd-HSA-NP did not. All studied MRI contrast agents showed significant CE in the blood, kidney, and liver ( p < .05). Gd-HSA-NP-FA elicited significantly higher CE in the blood than Gd-HSA-NP ( p = .0069); Gd-HSA-NP and Gd-HSA-NP-FA did not show CE in skeletal muscle and gallbladder; Gd-HSA-NP, but not Gd-HSA-NP-FA, showed CE in the cardiac muscle. Gd-HSA-NP-FA has potential as an MRI contrast agent in the brain.


2004 ◽  
Vol 37 (9) ◽  
pp. 3084-3091 ◽  
Author(s):  
Sander Langereis ◽  
Quido G. de Lussanet ◽  
Marcel H. P. van Genderen ◽  
Walter H. Backes ◽  
E. W. Meijer

2007 ◽  
Vol 13 (6) ◽  
pp. 717-721 ◽  
Author(s):  
J.M. Nielsen ◽  
B. Moraal ◽  
C.H. Polman ◽  
P. Poppe ◽  
M. de Vos ◽  
...  

Background Recently, a clinical classification system was described to determine whether symptoms and signs of patients presenting with a first episode suggestive of multiple sclerosis (MS) indicate the presence of monofocal or multifocal disease. Objectives To evaluate the value of this new classification system by comparing the results with those of simultaneously obtained magnetic resonance imaging (MRI) scans. Methods The 487 patients, randomised in the BENEFIT study, were centrally assessed using the new system and classified as monofocal or multifocal, based on clinical information by two neurologists masked for the MRI results. MRI analyses were performed by expert readers masked for the clinical classification. Results Patients classified as multifocal had more T2 hyperintense (median: 21 versus 15.5) and more T1 hypo-intense lesions (median: 2 versus 1) than those classified as monofocal. Patients classified at the local site as having evidence of a single clinical lesion, but reclassified centrally as having a clinical multifocal central nervous system presentation, had more T2 lesions than monofocal patients. In addition, patients with a multifocal presentation more often fulfilled the MRI criteria for dissemination in space, as incorporated in the International Panel (IP) diagnostic criteria for MS. Conclusion These data provide justification for the recently proposed clinical classification system to be used in patients who present with a first episode suggestive of MS, in that `multifocal', based on symptoms and signs, is associated with more lesions on MRI. Multiple Sclerosis 2007; 13: 717-721. http://msj.sagepub.com


Spine ◽  
2001 ◽  
Vol 26 (7) ◽  
pp. E149-E154 ◽  
Author(s):  
Jaro Karppinen ◽  
Antti Malmivaara ◽  
Osmo Tervonen ◽  
Eija Pääkkö ◽  
Mauno Kurunlahti ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document